Table 5.
Control | DIO | DIOcit–stat | |
---|---|---|---|
Srebf1 | 4.54 ± 0.95* | 0.60 ± 0.09#, * | 0.90 ± 0.09$ |
Lxrα | 1.37 ± 0.17 | 0.98 ± 0.17 | 1.08 ± 0.13 |
Chrebp | 0.84 ± 0.12 | 0.69 ± 0.07* | 0.81 ± 0.07 |
PPAR α | 0.33 ± 0.05* | 0.53 ± 0.09* | 0.46 ± 0.04* |
Pgc‐1α | 0.48 ± 0.05* | 0.41 ± 0.07* | 0.46 ± 0.10* |
PPAR γ | 0.96 ± 0.21 | 0.70 ± 0.14 | 0.86 ± 0.12 |
Fasn | 2.96 ± 0.99* | 1.07 ± 0.08# | 2.18 ± 0.32* |
Acc1 | 3.03 ± 0.93* | 1.12 ± 0.21 | 1.61 ± 0.27 * |
Scd1 | 0.48 ± 0.07* | 0.81 ± 0.23 | 1.03 ± 0.34 |
Gpam | 1.30 ± 0.07 | 0.84 ± 0.08# | 0.75 ± 0.03#* |
eNOS | 0.89 ± 0.15 | 1.10 ± 0.10 | 1.14 ± 0.22 |
Hprt, hypoxanthine guanine phosphoribosyl transferase; Pgc‐1α, peroxisome proliferator‐activated receptor gamma coactivator 1‐α.
Results are expressed relative to fasted values (mean ± SEM; n = 5 to 7 samples per group). Dietary interventions: standard diet (control), high fat–high sucrose diet (DIO) and DIO enriched in citrulline (2.5 g∙kg−1 body weight) and atorvastatin (10 mg∙kg−1 body weight) (DIOcit–stat).
P < 0.05, significantly different from fasted values;
P < 0.05, significantly different from control and DIO;
P < 0.05, significantly different from control.